uniQure (QURE) Q3 2026 Earnings Call Transcript

Image source: The Motley Fool.

DATE

Wednesday, Nov. 4, 2026

CALL PARTICIPANTS

• Senior Director of Investor Relations - Chiara Russo
• Chief Executive Officer - Matthew Kapusta
• Chief Medical Officer - Dr. Walid Abi-Saab
• Chief Customer and Strategy Officer - Kylie O'Keefe
• Chief Financial Officer - Christian Klemt

TAKEAWAYS

• Revenue -- $5.2 million for the third quarter, representing an increase from $3.7 million in the prior year period due to higher license revenue.
• AMT-130 PDUFA Date -- May 1, 2027, following the Food and Drug Administration's acceptance of the Biologics License Application for priority review.
• Cash and Investment Securities -- $768.4 million as of Sept. 30, 2026, which management expects will fund operations into 2030.
• 36-Month High-Dose Efficacy -- 75% slowing of disease progression on the cUHDRS and 60% on Total Functional Capacity compared with a propensity score matched external control.
• 48-Month High-Dose Efficacy -- 44% slowing on the cUHDRS and 61% slowing on Total Functional Capacity, reflecting clinical data from 12 patients four years after a single administration.
• Confirmatory Study Design -- approximately 200 patients randomized in a 2:1 ratio between AMT-130 high dose and standard of care, with a primary endpoint of Total Functional Capacity at 36 months.
• Research and Development Expenses -- $35.5 million for the quarter, driven by a $3.6 million increase in employee and contractor-related costs including share-based compensation.
• Selling, General and Administrative Expenses -- $23.9 million for the quarter, reflecting a $4.5 million increase primarily due to commercial recruitment efforts and information technology costs.
• Net Loss -- $61.2 million, or $0.88 per share, compared to a net loss of $80.5 million, or $1.38 per share, in the third quarter of 2025.
• AMT-260 Clinical Progress -- completed enrollment of seven patients in the second higher-dose cohort for refractory mesial temporal lobe epilepsy, with data expected in the first half of 2027.
• AMT-191 Enrollment -- resumed in the mid- and high-dose cohorts for Fabry disease after resolution of asymptomatic liver enzyme elevations.
• Commercial Treatment Centers -- targeting north of 15 centers for the initial U.S. launch, focusing on sites with existing Huntington's disease expertise and neurosurgical capabilities.
• Manufacturing Volume -- approximately 500 microliters per targeted infusion, which management noted allows for significantly higher patient yields per batch compared to intravenous therapies.
• Direct R&D Spend -- decreased by $2.3 million for the quarter, primarily due to a $4.1 million reduction in process validation expenses for AMT-130.
• Process Validation Expenses -- $4.1 million reduction for AMT-130 compared to the prior year period as the program moves toward potential commercialization.
• UK Marketing Authorization -- validated by the Medicines and Healthcare products Regulatory Agency, with health technology assessments planned with NICE and NHS England.
• Patient Functional Decline -- 0.1 point per year decrease in Total Functional Capacity for high-dose patients across the Phase I/II study, which management characterized as a remarkably slow decline for the disease.
• Confirmatory Study Timeline -- patient screening is expected to begin in the United States by the end of 2026.
• Non-Operating Items -- $7.6 million expense for the quarter, a $13.3 million decrease from the prior year primarily due to lower expenses related to pre-funded warrants.
• Updated 36-Month High-Dose Data -- 80% slowing on cUHDRS and 67% on Total Functional Capacity based on an expanded analysis of 15 patients.
• Cerebrospinal Fluid NfL -- remained near baseline levels at 48 months post-treatment in the high-dose cohort, serving as a biomarker of nerve cell damage.
• Field Team Build-out -- core medical, market access, and strategic account teams are expected to be fully in place by early 2027.

Need a quote from a Motley Fool analyst? Email pr@fool.com

RISKS

• Abi-Saab stated, "The FDA indicated that they are tentatively planning to discuss our application at an AdCom," which may impact the regulatory review timeline and requirements for the biologics license application.
• Abi-Saab noted that if the FDA requests four-year data during the review, "they consider that a major amendment and there will be a delay to PDUFA."
• Abi-Saab identified potential patient dropouts in the standard-of-care cohort of the confirmatory study as a risk, stating the company is "doing a number of simulation, and we have adjusted our sample size to match this."

SUMMARY

uniQure N.V. (NASDAQ:QURE) reported a transition toward potential commercial-stage operations following the regulatory acceptance of its lead gene therapy for Huntington's disease. Management stated that the company is preparing for a mid-2027 U.S. launch while initiating a global confirmatory study to support potential full approval. The company indicated that its current capital position provides the necessary resources to expand its commercial infrastructure and advance its broader clinical pipeline in epilepsy and Fabry disease through the end of the decade.

• Advisory Committee planning: Dr. Walid Abi-Saab stated, "The FDA indicated that they are tentatively planning to discuss our application at an AdCom," though the final decision remains with the agency.
• Total Functional Capacity significance: Dr. Walid Abi-Saab noted that TFC measures "whether a person can keep working, manage their finances, handle household responsibilities, take care of themselves day-to-day and live without full-time care."
• Launch factors: Kylie O'Keefe stated that treatment center capacity will be the primary factor shaping initial uptake during the early launch period.
• Confirmatory study priority: Matthew Kapusta stated the priority is to have the confirmatory study "well underway at the time of an approval decision."
• Global trial footprint: Management indicated the confirmatory study will include sites in North America, Europe, and Latin America to mitigate recruitment and dropout risks.
• Pipeline catalysts: Management expects to present updated clinical data for both AMT-260 and AMT-191 in the first half of 2027.

INDUSTRY GLOSSARY

• BLA (Biologics License Application): A request for permission to introduce a biologic product into interstate commerce.
• PDUFA (Prescription Drug User Fee Act): The date by which the FDA goal is to complete its review of a drug application.
• cUHDRS (composite Unified Huntington's Disease Rating Scale): A multi-modal rating scale used to track the clinical progression of Huntington's disease.
• TFC (Total Functional Capacity): A clinical endpoint that measures a patient's ability to maintain independence and perform daily activities.
• MHRA: The Medicines and Healthcare products Regulatory Agency, the regulatory body for medicines in the United Kingdom.
• MAA (Marketing Authorization Application): An application submitted to drug regulatory authorities to market a medicinal product.
• NfL (Neurofilament light chain): A protein biomarker found in cerebrospinal fluid that indicates nerve cell damage.
• AdCom (Advisory Committee): A meeting of independent experts convened by the FDA to review data and provide recommendations on drug approvals.
• NICE: The National Institute for Health and Care Excellence, which provides national guidance on health and social care in the United Kingdom.
• NHS England: The publicly funded healthcare system in England.

Full Conference Call Transcript

Operator: Hello, and thank you for standing by. My name is John, and I will be your conference operator today. At this time, I would like to welcome everyone to the uniQure Third Quarter 2026 Earnings Call. [Operator Instructions] I would now like to turn the call over to Chiara Russo, Senior Director of Investor Relations.

Chiara Russo: Thank you. Good morning and thank you for joining us for uniQure's third quarter of 2026 earnings call. Earlier this morning, uniQure released its financial results for the third quarter of 2026, and our press release is available on the Investors and Media section of our website at unicure.com. Our 10-Q was also filed with the SEC earlier today. Joining me on the call this morning are Matt Kapusta, Chief Executive Officer; Dr. Walid Abi-Saab, Chief Medical Officer; Kylie O'Keefe, Chief Customer and Strategy Officer; and Christian Klemt, Chief Financial Officer. After our formal remarks, we'll open up for an analyst Q&A. Before we begin, please note that we'll be making forward-looking statements during this investor call.

All statements other than statements of historical fact are forward-looking statements. They are based on management's beliefs and assumptions and on information available to management only as of the date of this conference call. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the factors described in uniQure's most recent SEC filings. Given these risks, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these statements even if information becomes available in the future. Now let me introduce Matt Kapusta, uniQure's CEO.

Matthew Kapusta: Good morning, and thank you for joining us on today's call. For the families who have waited generations for treatment for Huntington's disease, this quarter brought meaningful progress. As we announced on Monday, the FDA has accepted our biologics license application for AMT-130 and granted priority review with a target PDUFA date of May 1, 2027. In the United Kingdom, the MHRA has also validated our marketing authorization application. These are the first such marketing applications for a disease-modifying therapy for Huntington's disease, and it brings patients and families one step closer to a treatment option.

We greatly appreciate the engagement of both the FDA and the MHRA and their focus on the critical need for new therapies in Huntington's disease. I also want to acknowledge the commitment of our clinical, regulatory and CMC teams who prepared and submitted both applications in record time. And to every HD patient, family member and investigator who has trusted us with their hope, thank you. In September, we shared additional data from our ongoing Phase I/II studies, including updated 36-month data from all 27 evaluable patients across the low- and high-dose cohorts and for the first time, 48 months of follow-up after a single administration of AMT-130.

These data continue to show meaningful dose-dependent slowing of disease progression and reinforce our strong belief that AMT-130 has the potential to deliver treatment benefit to patients. We are also pleased to have aligned with the FDA on the key elements of the confirmatory study design, and we are making significant progress getting the trial up and running. We are fully committed to the timely execution of this study, and our priority is to have it well underway at the time of an approval decision. Walid will provide more detail on the confirmatory study later in the call. Regarding commercial preparations, we are making excellent progress ahead of potential U.S. launch in 2027.

We continue to build out our field, medical, market access and strategic account teams in a disciplined way and our financial strength provides the runway needed to execute this build-out. Kylie and Christian will provide more details on our commercial readiness and financial position later on the call. Beyond AMT-130, we continue to advance our broader pipeline. We have completed enrollment in the second dose cohort of our Phase I/IIa study of AMT-260 in refractory mesial temporal lobe epilepsy and have resumed enrollment in the Phase I/II study of AMT-191 in Fabry disease. For both programs, we expect to present new and updated data in the first half of 2027.

In summary, we are heading into the end of 2026 with strong momentum. Our priorities are clear, working closely with regulators as the application reviews proceed, executing our confirmatory study, advancing our pipeline and building the organization to prepare for the planned launch of AMT-130. With that, I will turn the call over to Walid to provide additional detail on AMT-130 and our pipeline. Walid?

Walid Abi-Saab: Thank you, Matt. Good morning and good afternoon, everyone. I'll start with AMT-130 in Huntington's disease, or HD. As Matt noted, the BLA is under priority review with the PDUFA date of May 1, 2027, and the MAA has been validated by the MHRA. Both submissions are based on the 36-month analysis we presented in September 2025. In that analysis, the high dose of AMT-130 showed a 75% slowing of disease progression on the composite Unified Huntington's Disease Rating Scale, or cUHDRS, and a 60% slowing on total function capacity or TFC, compared with the propensity score matched external control. Both results were statistically significant.

With the BLA now accepted and under active review, going forward, we will not be commenting on specific information requests made by the FDA, including questions regarding a potential AdCom. The FDA indicated that they are tentatively planning to discuss our application at an AdCom. As you're aware, scheduling an AdCom is within the sole discretion of the agency. In September 2026, we presented detailed analysis of a recent data cutoff. I will not repeat that today. Instead, I would like to focus on the progress we've made towards initiating the confirmatory study. Earlier this year, we reached alignment with the FDA on key elements of the design.

Specifically, this will be a randomized study with a 2:1 ratio of AMT-130 high dose to standard of care. It will include approximately 200 patients. The primary endpoint is TFC at 36-month. After 36-month, all standard of care participants will be offered AMT-130 in a separate open-label study. uniQure is fully committed to completing the study in a timely manner. Preparations started at the beginning of this year and have accelerated following alignment with the FDA. This will be a global study with sites across North America, Europe and Latin America. The protocol has already been submitted to institutional review boards or IRBs in the U.S., and we expect to begin patient screening by the end of this year.

I would like to take a moment to talk about TFC, the primary endpoint in the confirmatory study. This is a clinical endpoint that is very important, not only for regulators but also for people living with HD. Why is TFC important? TFC captures whether a person can keep working, manage their finances, handle household responsibilities, take care of themselves day-to-day and live without full-time care. For patients and families, these are not abstract measures. They are the difference between maintaining and losing independence, and they are directly related to quality of life. This is what patients and families care about.

In fact, it is what we heard from HD specialists at the 2 most recent scientific meetings we attended, the International Parkinson and Movement Disorder Society meeting in Seoul and the European Huntington's Disease Network meeting in Krakow. These specialists describe TSC as the endpoint they find most meaningful when talking with patients. Across our Phase I/II studies, TFC declined by less than 1/10 point per year in patients who received a high dose of AMT-130. This remarkably slow decline was consistent across all analyses and maintained through 4 years following treatment. Although these results come from a relatively small number of patients, they have never been seen before in HD.

Moving on to our other clinical programs, starting with AMT-260 for refractory mesial temporal lobe epilepsy. Following the initial 6-month data of the first low-dose cohort of 6 patients, which was presented in June, early in this quarter, we completed enrollment of the second cohort of 7 higher dose patients. We expect to present updated results from both cohorts in the Phase I/IIa study in the first half of 2027. Turning to AMT-191 for Fabry disease. In August, enrollment resumed in the mid- and high-dose cohorts. As a reminder, dosing has been paused per protocol in these 2 cohorts after asymptomatic liver enzyme elevations, which fully resolved following a course of immunosuppression.

We presented updated results in June from the March 15 cutoff, and we expect to share updated results from all 3 dosing cohorts in the first half of 2027. Now I will turn the call over to Kylie to discuss our recent patient advocacy work. Kylie?

Kylie O'Keefe: Thanks, Walid. With a known PDUFA date ahead of us, the question for our customer-facing team is no longer when. It's how. How do we make sure every piece of this patient journey is in place and well supported by the PDUFA date. So if approval is granted, we are ready to launch. For AMT-130, that journey runs from identifying an eligible patient through evaluation, surgery, follow-up and reimbursement. It involves many critical stakeholders. Our job is to ensure a smooth process for patients, families and the clinicians who care for them. For many of these families, the patient journey already runs through a familiar place, a specialty HD clinic they have relied on for years.

That is an important feature of this market as HD care is concentrated. A large share of diagnosed patients are seen at a number of specialty centers, many of them HDSA Centers of Excellence. That concentration will allow for a focused launch footprint. We continue to see strong enthusiasm from the physician and patient community. This quarter, our team spent significant time with the Huntington's disease clinical and patient communities. That included the International Congress of Parkinson's Disease and Movement Disorders, or MDS, and the EHDN Clinical Research Congress. These meetings came shortly after we submitted our BLA and U.K. MAA and shared our recent data.

That gave us a timely chance to hear directly from the physicians who care for HD patients every day. Our ongoing interactions tell us that physicians and families place great weight on preserving function and independence. And that is why the total functional capacity data Walid described resonates so strongly. We expect uptake to be shaped mainly by treatment center capacity in the early launch period, not by demand. That's why center readiness is our top operational priority and preparing to allow them to be operational as quickly as possible after a potential approval. Moving on to identifying treatment centers. AMT 130 is a one-time administered therapy through a neurosurgical procedure. Each treatment center, therefore, needs 3 capabilities working together.

HD neurology expertise to identify and evaluate patients, neurosurgical teams experienced in image-guided delivery and the ancillary infrastructure to support the procedure and product handling. We have identified priority centers in the U.S. and the U.K. Our readiness work at these centers covers 3 key areas: first, neurosurgical training and procedural support; second, product handling; and third, patient evaluation and referral pathways. Our goal is for a meaningful number of centers to be ready to treat eligible patients soon after a potential approval. Finally, access and our ongoing work with payers. We have been engaging with access stakeholders through appropriate preapproval information exchange.

These initial conversations cover the burden of Huntington's disease, the clinical data package and the economic profile of a onetime therapy. From early discussions, payers recognize the high unmet need in HD and the lack of any approved disease-modifying therapies. And there is a strong interest in learning more about AMT-130. In the U.K., we have begun engaging with NICE NHS England and are planning for health technology assessments so that access can follow as closely as possible after any potential MHRA decision. Finally, we continue to build the team that will make this launch a success. We expect to have our core team fully in place by early next year ahead of the PDUFA date.

We're hiring with care, bringing in people with deep experience in rare disease gene therapy and neurology launches. To summarize, we are preparing with urgency and discipline. Our goal is that if AMT-130 is approved, patients can move from referral to treatment as efficiently as possible. With that, I'll turn the call over to Christian for a financial update. Christian?

Christian Klemt: Thank you, Kylie. I'll now be sharing the financial highlights of the third quarter of 2026. Please refer to the earnings press release issued this morning and our quarterly filings with the SEC for additional detail. Revenue for the 3 months ended September 30, 2026, was $5.2 million compared to $3.7 million in the same period in 2025. The increase of $1.5 million is due to an increase in license revenue compared to the prior period. Research and development expenses were $35.5 million for the 3 months ended September 30, 2026, compared to $34.4 million during the same period in 2025.

The $1.1 million increase was primarily driven by $3.6 million increase in employee contractor-related expenses, including share-based compensation, which was partially offset by a $2.3 million decrease in direct research and development expenses. The decrease in direct research and development expenses resulted from a $4.1 million reduction in process validation expenses related to AMT-130, a $1.5 million increase in expenses related to AMT-260 and a $1.7 million increase in expenses related to preclinical activities and technology innovation projects. Selling, general and administrative expenses were $23.9 million for the 3 months ended September 30, 2026, compared to $19.4 million during the same period 2025.

The $4.5 million increase was primarily related to a $3 million increase in employee and contractor-related expenses, including share-based compensation, mainly as a result of the recruitment efforts over the last 12 to 15 months, a $0.7 million increase in professional fees and a $0.7 million increase in information technology costs to support the potential commercial launches of AMT-130. Cash, cash equivalents and investment securities totaled $768.4 million as of September 30, 2026, compared to $622.5 million as of December 31, 2025. We believe that uniQure continues to be well positioned to execute on its clinical and operational priorities. We expect that cash, cash equivalents and investment securities will be sufficient to fund operations into 2030.

I'll now turn the call back over to Matt.

Matthew Kapusta: Thank you, Christian. As you've heard today, the third quarter of 2026 was an important one for uniQure and for people impacted by Huntington's disease. We believe that AMT-130 has demonstrated a meaningful slowing of disease progression and has the potential to provide treatment benefit for people living with Huntington's disease. We now look forward to working with the regulatory agencies to bring AMT-130 to patients as soon as possible. With that, operator, please go ahead and open the call for questions.

Operator: [Operator Instructions] So our first question comes from the line of Debjit Chattopadhyay with Guggenheim Securities.

Debjit Chattopadhyay: I have a couple. First on AMT-130, if it becomes commercially available in the U.S. next year, how are you modeling potential dropouts from the standard of care cohort in the confirmatory study? And number two, are you evaluating any alternative delivery approaches to potentially expedite the procedure times?

Matthew Kapusta: Debjit, it's Matt here. Walid, do you want to take the first question on the confirmatory study?

Walid Abi-Saab: Sure. I'd love to. Yes. So Debjit, this is going to be a global clinical study. Early on, we're going to be prioritizing recruitment in the U.S. to get us up and running and be meaningfully recruited, but the reach will be global such that during the conduct of the study, we will be -- we will go to places where we will not be having AMT-130 on the market during the conduct of the study, and that will reduce this. In addition to this, we're doing a number of simulation, and we have adjusted our sample size to match this.

So this eventuality as well, as well as sort of analysis plans to deal with dropouts whenever they happen in the SOC. I turn it over to you, Matt.

Matthew Kapusta: Yes, Debjit, on the second question, there is actually a significant amount of work that's going on now looking at procedural adaptations. And these would be things that would potentially be implemented post approval. But a number of these things have the potential to meaningfully reduce procedural time and complexity.

Operator: Next question comes from the line of Paul Matteis with Stifel.

Matthew Ryan Tan: This is Matthew on for Paul. Congrats on the progress. I guess maybe a question for Kylie. How quickly would you anticipate patients will be able to get therapy, assuming the positive outcome from the PDUFA? And what would be the gating factor there? Would it be access? And then another quick follow-up. For the confirmatory study, would the eligibility criteria be similar to the Phase I/II, including the stage of the disease and maybe the striata volume requirements?

Kylie O'Keefe: Thank you very much for the first question. So with regards to what could potentially be gating factors, I think there's 2 elements to this. Access is, of course, one of them as well as ensuring that we have P&T approvals in the individual institutions to ensure that patients can get access to the therapy and that the institutions can get paid for that. However, what I would say, while these are traditional gating factors, the team is working very hard to ensure that we do as much preparation as possible ahead of a potential launch to ensure that this is streamlined in the best possible way.

So there's a lot of work going on in all the institutions to map the P&T processes, understand how often do they meet what are the requirements that are needed to secure approval and ensure that we're working with the institutions to provide as much information in advance so that it's streamlined at the point of launch. In addition to that, as I mentioned in the prepared remarks, the team is also working with payers on educating across both the unmet need in Huntington's disease as well as the AMT-130 data package to ensure that we're able to move as quick as possible post launch.

Walid Abi-Saab: So regarding the eligibility for the confirmatory study, that will be similar to the -- what we did report the Phase I/II, including the striatal volume as well.

Operator: Next question comes from the line of Joe Schwartz with Leerink Partners.

Joseph Schwartz: Congrats on all the progress. Given the FDA expects the confirmatory study to be well underway and potentially fully enrolled at the time of accelerated approval, and screening starts by year-end and the decision date is about 4 months later on May 1. We were wondering how many patients do you expect to have randomized or dosed by then? And then for the advisory committee, how do you keep the discussion on the 36-month analysis, which the FDA agreed supports the BLA rather than rearguing the 48-month primary analysis? And then any sense yet of timing or which committee?

Matthew Kapusta: Joe, thanks for the questions. Walid, do you want to take them one by one?

Walid Abi-Saab: Sure, happy to. So the FDA's fundamental intent for the confirmatory studies based on their January 25 guidance is that to make sure that they can be completed in a timely manner after approval. And we are confident we can demonstrate that. We've been starting -- we started to prepare for the study before we engaged fully with the FDA. And after we aligned with them, we accelerated that. Our goal is to run the study globally, as I indicated, across the U.S., Canada, North America, Latin America and Europe.

And we intend also to run it in places where there will not be access during the trial so that there will be lower risk of dropout, which is when the agency is, to a great extent, worried about it if we cannot complete the study. So with all of these elements in place and making sure that we demonstrate to the agency the full engagement and all the sites across the world that we've engaged with and the momentum for enrollment, we believe that we can present a credible path that would satisfy the agency. Regarding the AdCom and 48 versus 36-month, it's premature for us to position this. We will be ready to discuss any action.

But to a great extent, that will be depending on the agency's briefing book. As you know, in preparation for the AdCom, we are -- we will be preparing for any possible scenario. And we will have to gauge this based on what our specific questions are going to be raising for the AdCom and the briefing book supporting that. So we will get a chance to adjust in due course. And regarding the committee, I do not have any more information on this, definitely not from the FDA, but I would imagine it will be the typical committee that reviews cell and gene therapy and advanced therapies.

Operator: Next question comes from the line of Luca Issi with RBC Capital Markets.

Luca Issi: Congrats on the progress. Maybe, Walid can you confirm that you have yet to receive the day 74 letter? And then maybe bigger picture, can you just maybe educate us on what is usually included in that letter? Do you think the FDA will share some of their preliminary concerns in the context of the letter? I guess what I'm trying to ask here is whether there could be anything material in the letter that you need to disclose to the Street as well or not? And then maybe super quickly, SG&A obviously went up a little bit versus last year, you obviously preparing for the launch.

How should we think about the line item going forward maybe before and after the PDUFA?

Walid Abi-Saab: Yes. Thanks, Luca. Look, as we have indicated that since now, we are in active review process, we will not be providing any updates based on request for information or any other communication with the FDA. Of course, we will respond to them in due course. But unless things are material, we will not be communicating externally. In terms of usually comes at day 74, that would be one example. If the agency has -- they list their areas of concern and areas that they're focused on, that's usually part of that day 74.

Matthew Kapusta: Christian, do you want to answer the SG&A question?

Christian Klemt: Sure, happy to. Look, as you know, we don't give specific guidance. It shouldn't be surprised that SG&A spend will go up, but we'll maintain our disciplined approach. And it's all built into the runway guidance that we are capable of funding all our products into 2030.

Operator: Next question comes from the line of Joon Lee with UBS.

Joon Lee: Upon approval in May, how many patients would you be ready to dose in the U.S. and U.K. depending on the approval in U.K., obviously? And what is your manufacturing capacity? And last question, in the unlikely scenario where the FDA does not end up approving AMT-130, are you still obligated to complete the confirmatory trial?

Matthew Kapusta: Kylie, do you want to answer the first question on launch?

Kylie O'Keefe: Yes, absolutely. I think across the board from a patient perspective, it's a bit premature to provide specific patient estimates. I think what the team is working on extensively is ensuring that we're able to understand what the capacity is at each of the different centers, both in the U.S. and in the U.K. to understand what we think is a reasonable number of centers that need to be operationalized at launch to be able to try and meet the demand as quickly as possible.

So the team is working on that at the moment, and we're targeting a number of institutions that have both HDSA Centers of Excellence as well as ClearPoint in the same institution to ensure that patients are able to be evaluated, move to surgery and then back to neurology very seamlessly. And that is the work that's been ongoing. So while we are not quite there yet to give specific patient estimates, I think a reasonable analog is other gene therapies that have launched recently.

Matthew Kapusta: Yes. And maybe I'll answer the next 2 questions. Yes, on manufacturing capacity, we do not expect that to be a constraint. Remember, these are relatively small volumes that we're administering in a targeted and precise way per infusion, this is approximately 500 microliters. So the yields that we get in terms of number of patients that can be treated per batch is meaningfully higher than an IV administered medicine. On the third question regarding the confirmatory study, obviously, if we're not approved at the PDUFA date, we have to understand the reasons why and what our next steps are going to be.

If you're asking more about the obligations related to the confirmatory study, I mean, I certainly think we have a commitment to this patient community, and there would be an ethical obligation to continue with that study. I don't know if it's a legal obligation, but we're absolutely committed to the HD community and completing that study, whether or not the drug is approved and it's a confirmatory study or if it's a Phase III registrational study.

Operator: Next question comes from the line of Peyton Bohnsack with TD Cowen.

John Peyton Bohnsack: This is Peyton on for Joe. I guess, can you talk a little bit about the Phase III protocol or trial design and anything that's included to decrease any variability in the TFC measure or make sure that there is the highest chance to detect the difference between the 2 groups?

Matthew Kapusta: Sure. I assume you meant the confirmatory study, but Walid, why don't you answer that one?

Walid Abi-Saab: Yes. Thanks, Matt. Yes, I assume it was on the confirmatory study. So look, we take very good care to try and train the sites and do regular training to make sure that the measurement is really accurate. We're collaborating with HSG, where they are trying to standardize also the administration of the question for TFC. I mean TFC tends to be a bit less noisy. I mean, because this is not like subjective as much in terms of like to what degree you have an abnormal movement in various parts of your body like TMS, which has been shown to be excessively variable. TFC talks about like really crude measures. Can you work full-time? Can you work part time?

Can you take care of yourself? And those tend to be a bit much more consistent, I should say. And so we will be doing -- was there another part of the question that I'm missing?

Matthew Kapusta: No. I think he asked about...

Walid Abi-Saab: [indiscernible] Yes. And I wanted to mention also in powering the study, we also were careful. Of course, we don't want to be skating too close to the edge. We base it on information that we have from our ongoing study and took the necessary precautions to make sure that we will have enough power also considering potential dropout in the standard of care patients in the event that happens.

Operator: Next question comes from the line of Salveen Richter with Goldman Sachs.

Salveen Richter: On the launch here, how many certified neurosurgical centers do you expect to be fully trained and operationally prepared to dose commercial patients at approval? And what is the target throughput capacity here? And then maybe you could just also speak to how you're thinking about the label and whether it will reflect the broad Phase I/II inclusion criteria or whether it's restricted to specific striatal volume thresholds?

Kylie O'Keefe: Absolutely. So starting with the first question on number of neurosurgical centers and capacity. I think one of the things that is important to note is neurosurgical capacity differs quite dramatically from center to center. And so again, this has been a lot of the work that the team has been doing to understand how many functional neurosurgeons would be able to perform the procedure, how many operating rooms are in place that could be used and then calculating capacity based on those discussions with the centers. And so you see sometimes something from 2 a week to one a month, and it varies center to center.

So the team has been really thinking through what is the capacity at each institution. And as you look across the institutions, how does that scale up on a national level. We're still working through the number that we think will be available at launch. We're certainly going to be north of 15 centers. Could it be 30? Could it be 25? We're still working through that to understand what that could look like and how quickly we can operationalize these centers. But we're looking at centers with the highest potential capacity initially and then also adding additional centers from there.

With regards to the second part of the question associated with the label, I think it's a bit premature for us to comment on that. We're not at the stage of discussing the label with the FDA. However, the way we've thought about the addressable market is assuming stratal volume requirements. And then obviously, if that's not the case, then we would adjust that accordingly.

Operator: Moving on to our next question. It comes from the line of Yanan Zhu with Wells Fargo.

Matthew Kapusta: I think we should go to the next question, operator.

Operator: Next question comes from the line Ellie Merle with Barclays.

Eliana Merle: Just a follow-up to the earlier question on the number of patients that you anticipate having dosed in the confirmatory trial at the time of like potential approval. I guess, do you have plans to submit additional safety data to the FDA prior to accelerated approval after some of the patients in the confirmatory study have received the initial procedures? And then just a follow-up question on kind of like additional submissions to the FDA. I guess, if the FDA asked for the 4-year data, would that potentially warrant a major amendment as part of the review and how you're thinking about that as a potential scenario?

Matthew Kapusta: Thanks, Ellie. Walid, do you want to answer those?

Walid Abi-Saab: Sure. Regarding the number of patients, we're -- we are confident that we will be well underway by the time we reach PDUFA. And as I mentioned before, we have a lot of measures in place to be able to complete the study in a timely manner across the world. So pretty comfortable with that. In terms of the safety data, we will be providing a day 120 safety update, which is typical in this situation. And of course, if there's any patients that have been dosed in the confirmatory trial by that cutoff date, those would be included, should be any patient available by that time.

Regarding the 4-year data, there's been no discussion with the FDA to date regarding the 4-year data in terms of requesting it. But as I mentioned before, if this were to happen during the course of the review, we will not be communicating on this because during the process, unless something is material, we will not be communicating on this. Now as you mentioned, in the event they ask for it, we submit it and they consider that a major amendment and there will be a delay to PDUFA. Of course, that will become material, and we will be sharing that information with you.

Operator: Our next question comes from the line of Patrick Trucchio with H.C. Wainwright.

Luis Santos: Luis Santos in for Patrick. The question is focused on trying to understand a little bit what could happen in the U.K. and what steps need to happen assuming MHRA approval for fully funded? And then I would like to also ask a question on your epilepsy data coming up. And I was thinking if you could tell us a little bit more about how do you expect consistency in the patients that were treated with lower dose to inform the expectations for the higher dose?

Matthew Kapusta: Thanks for the questions. Do you want to answer the first question, Kylie, on the U.K.?

Kylie O'Keefe: Absolutely. Thanks, Matt. So with regard to your question around what happens from an access point of view to ensure that AMT-130 can be available for patients in the U.K. What would happen is we would undergo a NICE review. And from there, assuming success, we would begin NHS commissioning, NHS England, NHS Wales and so on and so forth, we would be commissioning with each of the individual countries in the U.K. So what we have done is begun engaging from an early scientific point of view with both NICE and NHS England to ensure that we're able to understand how they're viewing Huntington's disease, how they're viewing the AMT-130 package.

And then ultimately, we'll be in a position next year to be submitting the dossier to ensure that we're starting that process immediately upon approval.

Walid Abi-Saab: So for the AMT-260 question in MTLE, the really Phase I studies are there to learn. We dosed 6 patients in the low-dose cohort. We had great results in probably half the patients, and the others did not respond as well. We continue to follow them, and we will provide you also an update during the first half of next year on those patients. In addition, we now fully dosed 7 more patients in the higher dose cohort. And depending on the results, we will be able to interpret the data, one possibility. If we find very consistently positive results, then there would be one interpretation.

If that's not the case, then we need to figure out what would be the next step. So those would be part of the evaluation that we will do, and we will be sharing that information with you in the first half of next year. Another element we do in the Phase I study is to look at safety. And in the first cohort, that profile was fairly good at this stage of development. So we were encouraged by that, and that allowed us to go to the higher dose cohort. And again, we will be sharing with you the results in the first half of the year.

Operator: Next question comes from the line of Rudy Li with Wolfe Research.

Unknown Analyst: This is Devin on for Rudy. Just had a question on AMT-260. Can you talk about the differentiation versus Neurona and RTX-1001? And what is the bar for a no-go versus a go decision for the ongoing study?

Matthew Kapusta: Walid, do you want to take that?

Walid Abi-Saab: Sure. Well, again, we're early in development. So our goal right now is to evaluate the risk benefit and -- of this product and see whether there's clear evidence of activity. Our goal in the end would be to be best-in-class, and that will determine -- but that will be determined after an appropriately well-controlled trial that we can do. At this point, we are still in the signal detection mode. And as always, we are very careful in making a go/no-go decision. So we're still gathering that information. We will share with you an update early next year. And based on that, we will tell you which direction based on these data, we will be going next.

Operator: Next question comes from the line of Lachlan Hanbury-Brown with William Blair Chicago.

Lachlan Hanbury-Brown: I wanted to follow up on one of the prior questions about the confirmatory trial. You mentioned FDA guidance about having to be sort of well underway at the time of accelerated approval. But I feel like we've kind of seen apply that standard differently across programs. So I was just wondering if you had any sort of explicit discussions with them on how they're thinking about that stand and what well underway means in this instance.

Matthew Kapusta: Yes. I think I'll maybe just -- I think it's really the same answer to the question that Walid has mentioned previously. The FDA does have a wide discretion to determine what is meaningfully underway. The spirit of this, which applies to really all accelerated approvals, is that they want to ensure that the execution of confirmatory evidence generation is done in a timely manner. We -- they obviously are aware that we just are starting the confirmatory study. We've shared with them approximate time lines as part of our communication. The progress that we're making in getting the study up and running is accelerating.

We will have an initial focus on enrolling patients in the United States and centers that are already up and running. And we plan to have numerous centers outside the United States assuming the product is approved. So we're very confident and very committed to the study that we can complete it in a timely manner and then generate the data that is sufficient to support full approval.

Operator: Now our final question comes from the line of Sushila Hernandez with VLK.

Sushila Hernandez: So for the confirmatory study, could you expand on the primary analysis being assessed at 36 months, what is supporting this time point? And secondly, how many U.S. centers do you expect could administrate AMT-130 in the first 12 months after approval? How do you look at this development during the initial launch period?

Matthew Kapusta: Walid, do you want to take the first one? And then, Kylie, you can take the second?

Walid Abi-Saab: Sure. Yes. The primary analysis is essentially at 36 months TFC comparing our treated subjects to the standard of care control. Not sure if there's any need to elaborate more. This would be an MMRM analysis, which is typical of these types of studies. Kylie?

Kylie O'Keefe: Thanks, Walid. And with the second question, across the U.S., there's more than 60 HDSA Centers of Excellence. And then when you layer over the top of that centers that also have ClearPoint capabilities, you get to north of 100. This is obviously not what we're targeting in the first 12 months. And as I said earlier, that number has not been locked down yet. We're working through understanding the capacity at each of the different institutions in the U.S. and then trying to look at demand in the first 12 months and saying, what do we think is needed to be ready to go on day 1?

And then ultimately, how do we build that up over the first 6 months, 12 months, 18 months and so on. So we're going to be having a certain number of capacity at launch, which, as I said, is going to be north of 15 centers, whether it's 25, whether it's 30, that number has not been defined yet, and then we will build from there.

Operator: So this concludes the question-and-answer session and our call today. Thank you all for joining. You may now disconnect.

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.